Relatlimab

Relatlimab is a human monoclonal antibody that inhibits lymphocyte activation gene-3 (LAG-3), an immune checkpoint receptor expressed on exhausted T cells that suppresses antitumor immune responses when engaged by MHC class II ligands. In combination with nivolumab (anti-PD-1), relatlimab provides dual checkpoint blockade that synergistically restores T-cell function against tumors, with approval for unresectable or metastatic melanoma.

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

Yes, Relatlimab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.